A Syringe Maker Lost Its Tariff Fight. Now It's Betting on a Tax Bill.

A syringe that pulls the needle back into the barrel after a shot is a genuinely good invention. It lets a nurse give an injection and never touch the exposed needle — no needlestick, no risk of a blood-borne infection. Retractable Technologies has made them in Little Elm, Texas since 1989. So when the company put out a press release cheering a bill that would subsidize domestic manufacturing, the headline looks like ordinary corporate virtue-signaling.

It isn't quite that.

Read carefully, and it's the visible edge of a real strategy. Retractable supports Senator Marsha Blackburn's ONSHORE Manufacturing Act, which would hand out tax credits — 30% for advanced manufacturing equipment, 30% for facility modernization, and a 10.5% credit for domestic production — to companies making critical medical products in the U.S. The company's own description of the bill: "the spark American manufacturers need to rebuild our domestic medical base."

The reason this isn't empty PR is that Retractable is one of the companies most directly hurt by the exact problem the bill targets. It still sources most of its products from Chinese manufacturers — 62.6% of them in 2025. And the tariff on syringes and needles imported from China, set at 100% in 2024, had risen to 120% by March 2026.

Retractable fought the tariff in federal court. It filed a complaint at the Court of International Trade in late 2024, then quietly withdrew it in January 2025. It also cut jobs in April 2025 as it tried to reduce its dependence on China. In other words, it already lost the legal fight, and it has been moving manufacturing back to Texas on its own dime ever since. Domestic production climbed from 38% of units in the first half of 2025 to 42.4% a year later.

Here is what the operating numbers look like while it waits for the bill. Revenue was growing — $38.3 million in 2025, up 15.8%. But that is not the story. The company lost $21.2 million from operations that year, and the losses are not shrinking. In the first half of 2026, sales fell to $14.4 million from $18.7 million, and the operating loss widened to $11.3 million. Some of the second-quarter drop was timing: 2025 had an unusually heavy flu season in the spring.

The most revealing number is hiding inside the phrase "posts a profit." Retractable reported net income of $2.8 million in the second quarter of 2026. It came almost entirely from a $6.4 million gain on the sale of equity securities — investments the company cashed in, not syringes it sold. Strip that out and the quarter was an operating loss.

That is the real condition of the business. Retractable makes a product people genuinely want and keep using, for a concrete safety reason. But it has never quite found the economics. Its own reporting says operating costs stayed elevated through 2025 as it expanded facilities and moved production onshore, on top of roughly $1.8 million a year in tariff costs.

And here is the odd part for someone looking at a $22 million company: it's sitting on close to $40 million in cash and investments — more than its entire stock market value. In 2025 it ended the year with only $2.6 million in cash and funded itself through that securities portfolio. The Q2 profit came from selling a slice of it. The cushion is what keeps the company alive, and it is being spent down, not grown.

So the honest way to read the ONSHORE press release is as a bet about where Retractable thinks its future lies. Not in selling more syringes, and not in winning a lawsuit. In changing the tax code. The same government that doubled the tariff on its imports is being asked to subsidize the factory it is already building in response.

I don't know whether the bill passes, and a tax credit wouldn't fix demand or unit economics on its own. But the press release tells you which variable the company has decided matters most. If the bet is right, the operating losses narrow as onshore production scales. If it's wrong, the $40 million cushion is finite, and at a loss rate north of $20 million a year the next step is either a dilutive capital raise or a strategic outcome. Watch the operating loss and the cash balance — not the cheering.